Literature DB >> 9010097

Osteogenic sarcoma of the extremity with detectable lung metastases at presentation. Results of treatment of 23 patients with chemotherapy followed by simultaneous resection of primary and metastatic lesions.

G Bacci1, M Mercuri, A Briccoli, S Ferrari, F Bertoni, D Donati, C Monti, A Zanoni, C Forni, M Manfrini.   

Abstract

BACKGROUND: In the past 20 years, it has been demonstrated that the combination of surgery and chemotherapy improves the prognosis for patients with osteosarcoma of the extremity without detectable metastases at presentation. By contrast, the efficacy of chemotherapy coupled with aggressive surgery has not yet been well established for patients with metastatic disease at diagnosis. The current study evaluates the efficacy of chemotherapy associated with simultaneous surgery of primary and metastatic lesions in patients presenting with osteosarcoma of the extremity with lung metastases.
METHODS: Patients with lung metastases originating from an osteosarcoma of the extremity received chemotherapy (high dose methotrexate, cisplatin, doxorubicin, and ifosfamide) followed by simultaneous resection of primary and metastatic lesions and additional chemotherapy.
RESULTS: Between January 1993 and June 1995, 23 patients entered the study. After primary chemotherapy, lung metastases disappeared in three patients, whereas in four patients they remained surgically unresectable. All seven patients received surgical treatment of the primary tumor only. In the remaining 16 patients, a simultaneous resection of the primary and metastatic tumors was performed after chemotherapy. The resection of metastatic lesions resulted in a complete remission in 15 patients and an incomplete remission in 1 patient. All five patients who never achieved tumor free status died within a few months. Of the 18 patients who achieved radiologic remission at a 30-month follow-up (range, 14-50 months), 10 (55.5%) remained continuously free of disease, 7 relapsed with new metastases, and 1 died of toxicity. In 13 of the 18 patients who underwent a complete simultaneous resection of the primary and the metastatic lesions, or whose pulmonary metastases disappeared after chemotherapy, a strong correlation was found between degree of necrosis of the primary tumor and of the metastatic tumor.
CONCLUSIONS: In patients presenting with osteosarcoma of the extremity with lung metastases, the combination of aggressive chemotherapy with simultaneous resection of the primary and metastatic lesions improves traditionally negative outcomes. The strong correlation found between the histologic response of the primary and metastatic tumors supports the strategy, largely used currently in the neoadjuvant treatment of osteosarcoma, of tailoring postoperative chemotherapy on the basis of the histologic response of the primary tumor to preoperative chemotherapy.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9010097

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  27 in total

1.  Prognosticating metastatic osteosarcoma treated with uniform chemotherapy protocol without high dose methotrexate and delayed metastasectomy: a single center experience of 102 patients.

Authors:  V Nataraj; S Rastogi; S A Khan; M C Sharma; S Agarwala; S Vishnubhatla; S Bakhshi
Journal:  Clin Transl Oncol       Date:  2016-01-07       Impact factor: 3.405

2.  Accuracy of transmission CT and FDG-PET in the detection of small pulmonary nodules with integrated PET/CT.

Authors:  Suzanne L Aquino; Landon B Kuester; Victorine V Muse; Elkan F Halpern; Alan J Fischman
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-03-03       Impact factor: 9.236

3.  Management of small pulmonary nodules in patients with sarcoma.

Authors:  Tomoki Nakamura; Akihiko Matsumine; Rui Niimi; Takao Matsubara; Katsuyuki Kusuzaki; Masayuki Maeda; Tomoyasu Tagami; Atsumasa Uchida
Journal:  Clin Exp Metastasis       Date:  2009-05-23       Impact factor: 5.150

Review 4.  Progress in the chemotherapeutic treatment of osteosarcoma.

Authors:  Ya Zhang; Jingqing Yang; Na Zhao; Cao Wang; Santosh Kamar; Yonghong Zhou; Zewei He; Jifei Yang; Bin Sun; Xiaoqian Shi; Lei Han; Zuozhang Yang
Journal:  Oncol Lett       Date:  2018-09-12       Impact factor: 2.967

5.  Identifications of genetic differences between metastatic and non-metastatic osteosarcoma samples based on bioinformatics analysis.

Authors:  Baoyong Sun; Fangxin Wang; Min Li; Mingshan Yang
Journal:  Med Oncol       Date:  2015-04-02       Impact factor: 3.064

6.  Pulmonary metastases in children with osteosarcoma: characteristics and impact on patient survival.

Authors:  Darshana D Rasalkar; Winnie C W Chu; Vincent Lee; Bhawan K Paunipagar; Frankie W T Cheng; Chi Kong Li
Journal:  Pediatr Radiol       Date:  2010-09-03

7.  Location of pulmonary metastasis in pediatric osteosarcoma is predictive of outcome.

Authors:  Phillip A Letourneau; Lianchun Xiao; Matthew T Harting; Kevin P Lally; Charles S Cox; Richard J Andrassy; Andrea A Hayes-Jordan
Journal:  J Pediatr Surg       Date:  2011-07       Impact factor: 2.545

8.  Outcome of a pulmonary metastasectomy for an orthopedic malignancy.

Authors:  Ryuichi Suemitsu; Ichiro Yoshino; Makiko Tomiyasu; Kaoru Ondo; Hitoshi Ueda; Yukihide Iwamoto; Yoshihiko Maehara
Journal:  Jpn J Thorac Cardiovasc Surg       Date:  2005-08

9.  Osteosarcoma is characterised by reduced expression of markers of osteoclastogenesis and antigen presentation compared with normal bone.

Authors:  L Endo-Munoz; A Cumming; S Sommerville; I Dickinson; N A Saunders
Journal:  Br J Cancer       Date:  2010-06-15       Impact factor: 7.640

10.  Ezrin and alpha-smooth muscle actin are immunohistochemical prognostic markers in conventional osteosarcomas.

Authors:  Sébastien Salas; Catherine Bartoli; Jean-Laurent Deville; Jean Gaudart; Fréderic Fina; Arlette Calisti; Gérard Bollini; Georges Curvale; Jean-Claude Gentet; Florence Duffaud; Dominique Figarella-Branger; Corinne Bouvier
Journal:  Virchows Arch       Date:  2007-09-05       Impact factor: 4.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.